All times are Central European Summer Time (CEST)
K: Keynote; OP: Oral Presentation; RP: Rapid-Oral Presentation; TBA: To Be Announced
Monday 17 June
8:00-9:00
Welcome: Registration, Poster Hanging and Danish Pastry
8:15-8:45
Meet the Experts: Everything You Want to Know About ECM
9:00-10:15
Plenary Session: Welcome from the Chair and Keynote
Chair: Morten Karsdal
- Morten Karsdal: Welcome and Introduction
- Opening Ceremony
- [K1] Raghu Kalluri
10:15-10:45
Break: Coffee and Exhibition
10:45-12:20
Plenary Session: The Essential Components of the ECM
- Scott Friedman
- Sylvie Ricard-Blum
- [OP1] Jaimes Campos: “Common molecular (omics) fibrotic signature across organs affected by fibrosis in chronic diseases”.
- [OP2] TBA
- [OP3] TBA
12:15-13:45
Lunch
12:50-14:00
Industry-Sponsored Symposium: Targeting Fibrosis: Changing the ECM I
- Michael Cooreman: “PPARs: Regulators of tissue remodeling”.
- Giuseppe Mazza
- Paul Yaworsky
- Lara Perryman: “Finally an anti-fibrotic! Clinical efficacy of lysyl oxidase inhibitors”.
12:50-13:55
Industry-Sponsored Symposium: ECM Remodeling in Obesity and Metabolic Disorders: Causing Heart Failure
- TBA
- Zvonko Milicevic
- Joel Mathews
14:00-15:45
Plenary Session: The Importance of ECM in Cancer
- Thomas Cox
- Saurabh Gupta
- Janine Erler
- [OP4] Marina Pajic: “Reprogramming of pro-fibrotic immuno-suppressive pancreatic cancer environment by anti-fungal itraconazole enhances the overall anti-tumor response”.
- [OP5] Nicholas Willumsen: “Type III collagen pro-peptides in serum (PRO-C3) as a prognostic biomarker of survival in clinical cancer trials with a FDA letter-of-support”.
15:50-16:45
Industry-Sponsored Symposium: Quantifying Fibrosis
- Louis Petitjean
- Lars Johansson: “Non-invasive imaging of fibrogenesis and fibrosis”.
- Available
15:50-16:55
Industry-Sponsored Symposium: Unraveling ECM Dynamics: Techniques
- TBA
- TBA
- TBA
- Available
17:00-18:00
Poster Session 1
18:00-19:00
Welcome Networking Reception
Tuesday 18 June
8:00-9:00
Industry-Sponsored Symposium: Elastin and Collagens in Health, Aging and Disease
- Hervé Pageon
- Andrea Heinz: “Aging of elastic fibers in the skin and cardiovascular system”.
08:00-9:00
Industry-Sponsored Symposium: Exploring Anti-Inflammatory and Anti-Fibrotic Drugs: Model Systems
- Benjamin Simona
- Henrik Björk Hansen: “Distinct and shared therapeutic effects of semaglutide in preclinical models of fibrotic diseases”.
- Vince Fiore
9:00-10:35
Plenary Session: Dermatology and the Genetics of ECM
- Alexander Nyström: “What a genetic disease of the matrix can tell us about inflammation-driven fibrosis”.
- Simon Francis Thomsen: “Hidradenitis suppurativa and ECM”.
- [OP6] TBA
- [OP7] TBA
- [OP8] TBA
10:35-11:00
Break: Coffee and Exhibition
11:00-12:00
Rapid-Oral Sessions 1-3
- [RP1] Lena Willmer: “The efficacy of pharmacological interventions on ECM genes and proteins in human lung tissue and a microphysiological system for enhanced cultivation”.
- [RP2] Adam Bøgh Marstrand-Jørgensen: “Mapping Progression of DKD in ReninAAV UNx db/db mice utilizing time-series RNA sequencing”.
- [RP3] Hannah Tompkins: “High-dimensional imaging analysis reveals distinct immuno-matrix signatures across human lung diseases”.
- [RP4] Fabio Bignami: “The clinically relevant PRO-C3 biomarker: a new string to the bow of bleomycin model of pulmonary fibrosis”.
- [RP5] Paola Occhetta: “Pathological Hallmarks of Human Cardiac Fibrosis in a mechanically active Organ-on-Chip to Predict The Efficacy of Drugs and Advanced Therapies”.
- [RP6] Nicole Stupka: “ADAMTS-5 inhibition by GLPG1972 reduces muscle inflammation and fibrosis and improves contractile function in muscular dystrophy”.
- [RP7] Matej Andelic: “A Novel Biomarker of Type VII Collagen Degradation Is Increased in Patients with Atopic Dermatitis and Lowered with Immunosuppressant Treatment”.
- [RP8] Marcos Burger Ramos: “Engineering ECM-degrading bacteria to boost anti-cancer immunity in immune-excluded solid cancers”.
- [RP9] Andre Broermann: “Non-invasive assessment of hepatic fibrosis in preclinical rodent models”.
- [RP10] Si Yuen Lee: “Development of glioblastoma microenvironment using 3D printed polysaccharide bioinks for an in-vitro tumour model”.
- [RP11] Ellen Bamberg: “Obesity-Driven Changes in Breast Extracellular Matrix Exhibit a Pro-Angiogenic Phenotype”.
- [RP12] Giusy Di Conza: “Autotaxin targeting in metastatic PDAC: preclinical and preliminary clinical data”.
- [RP13] Thomai Tsapanou-Katranara: “Immune-cell specific biomarker of early intestinal inflammation: HNE degraded fragment of type III collagen is elevated in patients with IBD”.
- [RP14] Ling Wu: “The improvement of Bortezomib on cirrhosis and its potential mechanism”.
- [RP15-18] TBA
12:00-13:30
Lunch
12:30-13:30
Industry-Sponsored Symposium: Organ Fibrosis: Key Differences and Common Denominators
- Diana Julie Leeming
- Federica Genovese
- TBA
- TBA
12:30-13:30
Industry-Sponsored Symposium: Targeting Fibrosis: Changing the ECM II
- TBA
- TBA
- TBA
13:45-15:30
Plenary Session: Tissue Destruction in Inflammatory Diseases
Chair: Ali Mobasheri
- Florian Rieder
- Dinesh Khanna
- Oliver Distler
- [OP9] Kirsty Houslay: “RXC008, a highly potent GI-targeted pan-ROCK inhibitor, is a first-in-class approach to treat Fibrostenotic Crohn’s Disease”.
- [OP10] Marta Alexdóttir: “CPa9-HNE: A neutrophil-derived fragment of calprotectin measured in serum can monitor endoscopic and clinical disease activity in ulcerative colitis”.
15:45-16:45
Poster Session 2
17:00-17:45
Keynote
- [K2] Gisli Jenkins
19:00-24:00
Congress Dinner
Wednesday 19 June
08:00-08:50
Industry-Sponsored Symposium: The Fibro-Inflammatory Axis: Fibroblasts and Tissue Destruction
Chair: Ali Mobasheri
- Dana Orange
- Adam Croft
- Anne-Christine Bay-Jensen
8:00-9:05
Industry-Sponsored Symposium: Where Science Meets Business: The Transformative Role of Proteomics in Advancing Precision Medicine
- TBA
- Darcey Black: “Drug discovery and development in IPF: How can biomarkers support making key decisions?”
- TBA
8:15-8:45
Meet the Experts: The Best ECM Papers Published
9:15-10:50
Plenary Session: Treating the ECM in Lung Diseases
- TBA
- Rachel Chambers
- [OP11] Katy Roach: “Proteomic Evaluation of a Human Lung model of Fibrosis for Novel Therapeutic Target Selection”.
- [OP12] Iain Stewart: “Genetic burden of extracellular matrix components in pulmonary fibrosis”.
- [OP13] Paul Yaworsky: “Anti-WISP1 (MTX-463) as a Novel Potential Therapy for Idiopathic Pulmonary Fibrosis”.
11:00-12:45
Plenary Session: ECM Remodeling in Liver and Heart Diseases
- Aleksander Krag: “ECM and the Liver: Ready for Clinical Translation?”
- Judith Ertle
- Faiez Zannad: “Clinical characterization of ECM related mechanisms in cardiovascular disease and therapy”.
- [OP14] Erik Tillman: “EFX improved biomarkers of fibrogenesis-to-fibrolysis balance consistent with a shift to beneficial ECM remodeling in patients with F2-F3 MASH”.
- [OP15] TBA
12:45-13:15
Light Lunch
13:15-14:30
Plenary Session: Keynote, Congress Summary and Abstract Awards
Chair: Morten Karsdal
- [K3] Detlef Schuppan
- Congress Summary
- Abstract Awards